Novel Dry Eye Drug Delivery
IACTA Pharmaceuticals careers
IACTA has licensed the rights to NM133, a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye. This unique nanotechnology allows a hydrophobic drug to be encapsulated and delivered to the tissues of the eye with favorable tissue permeation.
IACTA Pharmaceuticals hasn't added any jobs yet
Get notified when IACTA Pharmaceuticals posts new jobs.
Damon Burrows
CEO - IACTA Pharmaceutics
IACTA Pharmaceuticals was established by former key Allergan executives to develop and commercialize innovative eyecare products.
Amgen • Rico • 4 days ago
Pacific Biosciences • Menlo Park • $148k – $222k • 6 days ago
Glaxosmithkline • Seattle • $158k – $264k • 6 days ago
Noble Biomaterials • Scranton • $64k – $84k • 1 week ago
Penumbra • Roseville • $126k – $180k • 2 weeks ago